Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models

Table 2

In vitro antiproliferative activity of selective receptor tyrosine kinase inhibitors against human DTC cells.

Tissue type	Cell line	VEGFR2i^1		FGFRi		FGFRi		KITi		PDGFi
		Sorafenib		PD166866		PD173074		Glivec		Ki6783
		(μM)	T/N^4	(μM)	T/N^4	(μM)	T/N^4	(μM)	T/N^4	(μM)	T/N^4
Normal	Nthy-ori 3-1	5.7	—	14	—	4.6	—	20	—	1.7	—
DTC^2	K1	5.2	0.91	29	2.07	11	2.39	21	1.1	9.2	5.4
	RO82-W-1	4.2	0.73	1.9	0.14	0.63	0.14	21	1.1	2.5	1.5
	FTC-133	5.5	0.96	23	1.64	9.7	2.11	23	1.2	8	4.7
	FTC-236	7.7	1.35	30<	2.14<	4.3	0.93	30<	2.14<	30<	2.14<
	FTC-238	7.3	1.28	21	1.5	9.4	2.04	24	1.3	2	1.2

Inhibitor.
²Differentiated thyroid cancer.
³IC₅₀: the half maximal inhibitory concentration.
⁴T/N ratio of IC₅₀ values of thyroid cancer cell lines to that of Nthy-ori 3-1 cells.